Most Recent Articles by Steve Duffy
Tozadenant is being investigated as an adjunctive treatment to levodopa in Parkinson disease patients to reduce 'off' time.
The FDA has cleared Nexstim's NBT system for the treatment of major depressive disorder.
The primary endpoint of the study is the change from baseline of the Yale Global Tic Severity Scale between placebo and active treatment groups at the end of week 12.
Over 33% of older adults have reported using medication to help them sleep.
The system includes a detect-and-respond mode, which is designed to prevent seizures before they start and deliver therapy to stop them if they do.
More Articles by Steve Duffy
Neurology Advisor Articles
- Coffee Consumption May Decrease Stroke Risk
- Prochlorperazine More Effective Than Ketamine for Headache Relief in the Emergency Department
- CTE Confirmed With Antemortem PET Imaging, Autopsy in Professional Football Player
- Intranasal Sumatriptan More Effectively Reduces Migraine-Associated Nausea
- Neuropsychiatric Conditions Common in Relatives of Patients With Amyotrophic Lateral Sclerosis
- Treating Cluster Headache: Weighing Current Therapies
- Alzheimer Disease Linked to High Cumulative Doses of Zolpidem in Elderly
- NBT System Gets FDA Clearance for Depression Treatment
- Better Migraine Pain Relief With IV Non-Opioid Combination vs IV Hydromorphone
- FDA Approves Myasthenia Gravis Treatment
- Reports of Agranulocytosis Prompt Monitoring for Investigational Parkinson's Drug
- Nusinersen Improves Motor Function, Survival in Infants With Spinal Muscular Atrophy
- Noninvasive Brain Stimulation System Approved for Depression
- Hypertension Guidelines Updated by AHA/ACA
- Bone Mineral Density Associated With Intracranial Aneurysm Presence, Size